UK Eases Access To GW's Cannabidiol Epilepsy Drug
Epidyolex Also Being Rolled Out In EU Markets
Executive Summary
The easing of the regulations governing GW Pharmaceuticals’ groundbreaking epilepsy drug in the UK will be followed by wider availability in Europe as pricing and reimbursement discussions continue.
You may also be interested in...
GW Pharma Soars On Strong Epidiolex Sales
With its lead cannabinoid product Epidiolex continuing to advance, the London-headquartered, NASDAQ-listed firm has begun late-stage trials in the US with nabiximols, which looks likely to become its second approved drug.
GW Gets Two Cannabis-Based Meds Backed By NICE
Two cannabis-based drugs developed by GW Pharmaceuticals have been approved for use on the NHS in England for the first time and will be prescribed to patients with epilepsy and multiple sclerosis.
GW Pharmaceuticals Scores EU First For Cannabinoid Drug
GW Pharmaceuticals is pressing on with plans to launch its epilepsy treatment Epidyolex in the EU, starting with France and Germany.